Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 48,379 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AS+ Clear all
Terminated Not applicable Interventional

Treadmill Training in Fragile X-associated Tremor/Ataxia Syndrome

NCT04428567
View directory record Official record
Conditions
Fragile X Associated Tremor-ataxia Syndrome
Interventions
Dual-Task Treadmill exercise + Cognitive Training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 24, 2026, 10:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

NCT06998407
View directory record Official record
Conditions
HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions
AVZO-021, Fulvestrant, Letrozole, AVZO-023
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 10:03 PM EDT
Terminated Not applicable Interventional Results available

Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

NCT00716807
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome
Interventions
nalbuphine plus naloxone, nalbuphine plus placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

NCT01672892
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications, Radiation Toxicity, Urinary Complications, Urinary Tract Toxicity
Interventions
Standard radiation therapy, intensity-modulated radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
129
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Understanding Perspectives of Frequently-Admitted Hospital Patients

NCT03097640
View directory record Official record
Conditions
Continuity of Patient Care, High Utilizers of Hospital Care, Patient-Centered Care
Interventions
CHAMP
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 24, 2026, 10:03 PM EDT
Not listed Not applicable Interventional

A Novel Non-Pharmacological Treatment of Diabetic Neuropathy

NCT05414968
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Non-pharmacological Heat, Pressure, and Vibration
Device
Lead sponsor
Auburn University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

NCT02504489
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel + Plinabulin (DP), Docetaxel (D)
Drug
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Chandler, Arizona • Anaheim, California • Whittier, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 24, 2026, 10:03 PM EDT
Terminated Not applicable Interventional Results available

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

NCT00685750
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Collection of tumor and blood samples
Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Park Ridge, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 24, 2026, 10:03 PM EDT
Terminated Phase 1 Interventional

Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

NCT02510950
View directory record Official record
Conditions
Glioblastoma Multiforme, Astrocytoma, Grade IV
Interventions
Personalized peptide vaccine, Poly-ICLC, Temozolomide
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 24, 2026, 10:03 PM EDT
Recruiting Phase 4 Interventional Results available

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

NCT03096418
View directory record Official record
Conditions
Breast Neoplasm Female
Interventions
Paclitaxel
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

NCT01488318
View directory record Official record
Conditions
Squamous Cell Carcinoma Of The Head And Neck
Interventions
Cetuximab, Dasatinib
Drug
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Trusculpt (Radio Frequency) Device For Thigh Circumference Reduction

NCT01665118
View directory record Official record
Conditions
Body Fat
Interventions
Trusculpt (Radio Frequency) Device
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Brisbane, California • Montclair, New Jersey • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

NCT04660890
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Phase 2Phase 3 Interventional

Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes

NCT01068197
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus
Interventions
Low Glycemic Load Diet versus Low Fat Diet
Behavioral
Lead sponsor
Nazrat Mirza
Other
Eligibility
7 Years to 14 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 24, 2026, 10:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Primary Connections for Youth and Families

NCT05964010
View directory record Official record
Conditions
Substance Use
Interventions
Standard Screening, Standard Psychoeducation, Standard Brief Negotiated Interview (BNI), Standard Referral to Treatment (RT), Family Screening, Family Psychoeducation, Family Brief Negotiated Interview (BNI), Family Facilitated Conversation (FC) & Referral to Treatment (RT)
Behavioral
Lead sponsor
The National Center on Addiction and Substance Abuse at Columbia University
Other
Eligibility
12 Years to 17 Years
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 24, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

NCT01036113
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
EZN-2208
Drug
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
36
States / cities
Sedona, Arizona • Tucson, Arizona • Murrieta, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 24, 2026, 10:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acorai Machine Learning Generalization (MLG) Study

NCT05835024
View directory record Official record
Conditions
Heart Failure
Interventions
Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1, Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2
Device
Lead sponsor
Acorai AB
Industry
Eligibility
18 Years and older
Enrollment
1,602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
10
States / cities
Conway, Arkansas • Little Rock, Arkansas • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 24, 2026, 10:03 PM EDT
Withdrawn Phase 1 Interventional

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

NCT00957320
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Sirolimus, PEG-asparaginase
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 24, 2026, 10:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

NCT04729959
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Interventions
Atezolizumab, Biospecimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Tocilizumab
Biological · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
110
States / cities
Anaheim, California • Bellflower, California • Los Angeles, California + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intermittent Hypoxia and Inspiratory Threshold Loading to Enhance Inspiratory Muscle Function

NCT03029559
View directory record Official record
Conditions
Intermittent Hypoxia
Interventions
Intermittent Hypoxia, Inspiratory Threshold Loading, Sham Intermittent Hypoxia
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

NCT00151879
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.

NCT04415879
View directory record Official record
Conditions
COVID-19
Interventions
N-95 Respirator, Cloth Face Mask
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 24, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 24, 2026, 10:03 PM EDT